ArticleAntimicrobial agents and chemotherapy2025
Cethromycin pharmacokinetics and pharmacodynamics for single dose cure of
Grace Kennedy, Rachel M West, Kristin Poti, Bryce Bobb, Matthew M Ippolito, Mark A Marzinke, Nikola Kaludov, David J Sullivan
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Grace KennedyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Rachel M WestW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Kristin PotiW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Bryce BobbW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Matthew M IppolitoW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Mark A MarzinkeClinical Pharmacology, Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-1670-8786 Nikola KaludovAliQuantumRx Inc, Baltimore, Maryland, USA.
David J SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-0319-0578 Funding
Clinical Pharmacology of Malaria Control and Elimination: Pharmacodynamics ofArtemisinin-based Combination Agents and their Barriers to Drug ResistanceK23AI139343 · NIAID · JOHNS HOPKINS UNIVERSITY · PI IPPOLITO, MATTHEW MICHAEL · 2020 to 2023
$773kQuantum model repurposing of cethromycin for liver stage malariaR21TR001737 · NCATS · JOHNS HOPKINS UNIVERSITY · PI SULLIVAN, DAVID JOSEPH · 2016 to 2017
$612kMaryland TEDCONational Institute of Allergy and Infectious Diseases K23AI139343NCATS NIH HHS R21 TR001737NCATS NIH HHS R21TR001737NIAID NIH HHS K23 AI139343
6 · The paper itselfAbstract
Cethromycin combines a quinoline nucleus and a macrolide for broad-spectrum antibacterial and antiprotozoan activity. Here, we characterized the murine pharmacokinetics and
Indexed as
AntimalarialsLiverMalariaPlasmodium bergheiAnimalsFemaleHepatocytesHumansMicePlasmodium falciparumAntimalarialsantimalarial agentsblood stagecethromycinchemotherapyliver stage
Identifiers
PMID40525408
PMCPMC12326986
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390